Compared to the placebo, there was a 16% reduced risk of developing urinary tract infections with SGLT2 inhibitors yet did not reach statistical significance (RR: 0.84, 95% CI: 0.56–1.27, p = 0.41, I2 = 0%) (Figure 12). The gene discussed is SLC5A2; the disease is urinary tract infection.